methylprednisolone sodium succinate / Generic mfg. - LARVOL DELTA

Fulminant immune checkpoint inhibitor encephalitis associated with nivolumab: Case report and review of the literature (ASH 2025) - "Case Presentation: Within 24 hours of initiating nivolumab combined with brentuximab (an antibody-drug conjugate), a White male in his 70s with recurrent Hodgkin lymphoma and history of cutaneous T-cell lymphoma presented with altered mental status, status epilepticus, and abnormal signal in the bilateral temporal lobes on brain magnetic resonance imaging (MRI)...Following multidisciplinary consultation, the patient was ultimately diagnosed with ICI-encephalitis and begun on empiric treatment with intravenous methylprednisolone dosed 1 g/day for 5 days, followed by 5 days of intravenous immunoglobulin (IVIG)... This case serves as a safety signal for fulminant irAE following nivolumab administration. According to available literature, this represents the most rapidly-presenting case of fulminant irAE following administration of an ICI."

Case report • Checkpoint inhibition • Clinical • Review • CNS Disorders • Cutaneous T-cell Lymphoma • Epilepsy • Genetic Disorders • Hematological Malignancies • Hodgkin Lymphoma • Infectious Disease • Lymphoma • Oncology • Skin Cancer • T Cell Non-Hodgkin Lymphoma

Multisystem flare of systemic lupus erythematosus presenting with severe warm autoimmune hemolytic anemia: A diagnostic and transfusion challenge (ASH 2025) - "Case Presentation: A 43-year-old woman with established SLE (diagnosed in 2016), previously treated with hydroxychloroquine and methotrexate, presented with fatigue, jaundice, dark urine, and right upper quadrant discomfort...The patient was premedicated with IV methylprednisolone and diphenhydramine and transfused with two units of the least incompatible RBCs...She received methylprednisolone 1 g IV daily for three days, followed by oral prednisone (1 mg/kg/day)... Severe wAIHA in SLE demands rapid diagnosis, interdepartmental collaboration, and flexibility in transfusion strategies. The least incompatible RBC transfusion, combined with immunosuppressive therapy, can be lifesaving. Comprehensive evaluation of systemic involvement is essential in such complex flares."

Anemia • Autoimmune Hemolytic Anemia • Autoimmune Hepatitis • Hematological Disorders • Hepatology • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Lupus • Solid Tumor • Systemic Lupus Erythematosus • Uterine Leiomyoma

Inflammation-triggered thrombotic thrombocytopenic purpura: A case series highlighting diagnostic pitfalls and atypical presentations (ASH 2025) - "TTP was diagnosed clinically and treated with IV methylprednisolone and plasmapheresis, leading to full hematologic recovery...Early recognition and treatment can be lifesaving. These cases support the notion that inflammation alone can precipitate clinically significant TTP-like syndromes and challenge the over-reliance on ADAMTS13 for diagnosis."

Clinical • Acute Kidney Injury • Addiction (Opioid and Alcohol) • Diabetes • Gastroenterology • Hematological Disorders • Hepatology • Inflammation • Metabolic Disorders • Nephrology • Pancreatitis • Renal Disease • Thrombocytopenia • Thrombocytopenic Purpura • Type 2 Diabetes Mellitus

Rare but not forgotten, a case of evan's syndrome. (ASH 2025) - "The patient received intravenous methylprednisolone followed by oral prednisone...A systematic review of 10 studies reported universal use of corticosteroids as first-line therapy, with rituximab used in 18.4% and splenectomy in 16% of cases...This case highlights the importance of recognizing Evans syndrome as a potential manifestation of immune dysregulation. Thorough evaluation for underlying autoimmune, infectious, or lymphoproliferative disorders is essential to guide treatment decisions and inform prognosis."

Clinical • Autoimmune Hemolytic Anemia • Endocrine Disorders • Hematological Disorders • Hepatology • Human Immunodeficiency Virus • Immune Thrombocytopenic Purpura • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Neutropenia • Rheumatoid Arthritis • Rheumatology • Systemic Lupus Erythematosus • Thrombocytopenia • Thrombocytopenic Purpura • HP

IVIG successfully halts a recurrent hyperhaemolysis syndrome in a young patient with sickle cell crisis (ASH 2025) - "His hemoglobin dropped from 8 to 5.6 mg/dl and the patient was transfused 2 units of packed red blood cells with methylprednisolone 40 mg IV prior, his hemoglobin dropped quickly afterward, reticulocytes spiked from 11% to 27%, Ferritin increased to 33K, further transfusions resulted in worse response. The patient's significant response to IVIG along with methylprednisolone offers a valuable treatment option to guide physicians' decisions in the future. Initiating treatment with the biologic Tocilizumab is also an option which has shown benefit in similar cases."

Clinical • Cardiovascular • Genetic Disorders • Hematological Disorders • Hepatology • Pulmonary Embolism • Respiratory Diseases • Sickle Cell Disease

Warm autoimmune hemolytic anemia following epstein-barr virus reactivation: An uncommon clinical association (ASH 2025) - "His only medications were atenolol and atorvastatin, and he denied use of herbal supplements or over-the-counter drugs... Warm AIHA is most commonly idiopathic but can also occur secondary to various conditions, including rheumatologic diseases (e.g., systemic lupus erythematosus), chronic lymphoblastic leukemia, non-Hodgkin's lymphoma, certain medications (e.g., cephalosporins, piperacillin), and infections...Initial corticosteroid therapy varies widely during the first 72 hours, ranging from 1–2 mg/kg of prednisone every 8–12 hours to high-dose intravenous methylprednisolone (250–1000 mg/day)...In cases refractory to steroids, additional therapies such as mycophenolate mofetil or sirolimus may be considered. This case highlights a rare presentation of warm AIHA likely triggered by EBV reactivation, an association that is infrequently reported in the literature."

Clinical • Anemia • Autoimmune Hemolytic Anemia • Chronic Lymphocytic Leukemia • Cytomegalovirus Infection • Dyslipidemia • Epstein-Barr Virus Infections • Hematological Malignancies • Hepatology • Human Immunodeficiency Virus • Hypertension • Immunology • Infectious Disease • Inflammatory Arthritis • Leukemia • Lupus • Lymphoma • Non-Hodgkin’s Lymphoma • Pulmonary Disease • Rheumatology • Systemic Lupus Erythematosus • HP

Final results of a multi-center phase 2 trial of isatuximab-lenalidomide in patients with high risk smoldering multiple myeloma (HRSMM) (ASH 2025) - P3 | "Randomized trials of lenalidomide (LEN) +/- dexamethasone vs. observation (E3A06,QuiReDex), carfilzomib-lenalidomide-dexamethasone (KRd) with transplant, consolidation, andmaintenance (GEM-CESAR), and anti-CD38 monoclonal antibodies alone (CENTAURUS) or with KRd(ASCENT), have all shown efficacy in terms of response and progression free survival (PFS) in suchpatients; some have also reported improved overall survival (OS)... Patients were treated on 28-day cycles with ISA 20 mg/kg IV on days 1, 8, 15, and 22 of cycle (C)1, days 1 and 15 of C2-6, and day 1 of C7-30, together with LEN 25 mg PO on days 1-21 of cycles 1-6; methylprednisolone 100mg iv was given prior to each ISA infusion... ISA-LEN is a well-tolerated therapy for high risk smoldering multiple myeloma, with a 4-yearPFS of 94.3%. The final results of this phase 2 trial compare favorably with the natural history of PETHEMAHRSMM patients (Perez-Persona et al. Blood 2007), while limiting both steroid and LEN use."

Clinical • P2 data • Constipation • Gastroenterology • Gastrointestinal Disorder • Leukopenia • Multiple Myeloma • Neutropenia • Pancreatic Adenocarcinoma • Pancreatic Cancer • Smoldering Multiple Myeloma • Thrombocytopenia

PA38 A rare case of facial atrophy in a 10-year-old girl. (PubMed, Br J Dermatol) - "In our case, methotrexate and prednisolone failed to adequately control disease progression. As such, the patient was commenced on pulsed intravenous methylprednisolone...This case underscores the challenges in diagnosing and managing progressive hemifacial atrophy, highlighting the crucial role of integrating clinical correlation with investigative findings. It also emphasizes the need for a multidisciplinary approach to effectively address such cases."

Journal • Dermatology • Immunology • Mood Disorders • Rheumatology • Scleroderma • Systemic Sclerosis

BI03 Erythrodermic psoriasis following second cycle of cemiplimab: a case report. (PubMed, Br J Dermatol) - "The patient was admitted and commenced on intravenous methylprednisolone, leading to symptom resolution within 7 days. Understanding the pathophysiological mechanisms underlying these toxicities is essential for optimizing treatment strategies, minimizing adverse effects without compromising ICI efficacy, and ultimately prolonging patient access to immunotherapy. Further research into immune-related dermatological conditions may also provide valuable insights into the molecular mechanisms governing endogenous dermatological diseases, offering new avenues for targeted dermatological therapies."

IO biomarker • Journal • Alopecia • Dermatology • Dermatopathology • Immunology • Oncology • Psoriasis • Squamous Cell Carcinoma • Vitiligo • IL17A • IL23A

Short and Long-Term Effects of Intravenous Methylprednisolone and Plasma Exchange Combination in NMOSD Attacks. (PubMed, Noro Psikiyatr Ars) - "Age and baseline EDSS scores were identified as key factors influencing post-treatment improvement. Our results suggest that the addition of PLEX to IVMP treatment might be suitable especially for severe NMOSD attacks."

Journal • CNS Disorders • Immunology • Inflammation • Neuromyelitis Optica Spectrum Disorder • Ocular Inflammation • Ophthalmology • Optic Neuritis • Rare Diseases

Unicentric Castleman disease with paraneoplastic pemphigus and follicular dendritic cell sarcoma: A case report. (PubMed, Oncol Lett) - "Initial therapy comprised high-dose methylprednisolone, intravenous immunoglobulin and thalidomide, followed by surgical resection and adjuvant thalidomide-cyclophosphamide-prednisone. Postoperatively, inflammatory indices normalized and mucocutaneous lesions partially improved; nevertheless, the patient died of respiratory failure 6 months after surgery. In summary, the present case report aimed to provide valuable references and experiences for clinicians in the diagnosis and treatment of CD featuring PNP and FDCS."

Journal • Oncology • Rare Diseases • Respiratory Diseases • Sarcoma • Solid Tumor • CD21 • CD68 • CR1 • CXCL13 • FCER2

Castleman Disease in a Child: A Rare Cause of Persistent Cervical Lymphadenopathy. (PubMed, Cureus) - "The patient received intravenous methylprednisolone, followed by three cycles of rituximab with partial reduction of lymphadenopathy. Histopathology confirmed the diagnosis, showing atretic germinal centers, hyalinisation, intrafollicular vascular proliferation, and plasma cell infiltrates. This case highlights the diagnostic challenges of Castleman disease in children, its overlap with common conditions like tuberculosis, and the importance of multidisciplinary evaluation and combined medical-surgical therapy for optimal outcomes."

Journal • Epstein-Barr Virus Infections • Fatigue • Hematological Disorders • Hepatology • Infectious Disease • Oncology • Pain • Pulmonary Disease • Rare Diseases • Respiratory Diseases • Tuberculosis

Islet Transplantation in Patients With "Brittle" Type I Diabetes (clinicaltrials.gov) - P=N/A | N=20 | Recruiting | Sponsor: University of Chicago | Trial primary completion date: Sep 2025 ➔ Jun 2030

Trial primary completion date • Diabetes • Metabolic Disorders • Severe Hypoglycemia • Transplantation • Type 1 Diabetes Mellitus

GAIN-CTNNB1: Gene Replacement Therapy for Treatment of Paediatric Patients With CTNNB1 Neurodevelopmental Syndrome (clinicaltrials.gov) - P1/2 | N=12 | Recruiting | Sponsor: CTNNB1 Foundation

New P1/2 trial • Pediatrics

Sustained anti-PD1 response in refractory EBV-positive DLBCL with CNS involvement in an immunocompetent patient (SNO 2025) - "His disease was refractory to MR-CHOP (high-dose methotrexate, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), as well as to R-ICE (rituximab, ifosfamide, carboplatin, and etoposide) combined with intrathecal methotrexate (IT-MTX). Given that his tissue demonstrated >70% of neoplastic B cells positive for PD-L1 staining, the patient was started on anti-PD-1 (anti-programmed cell death protein 1) therapy with nivolumab (240 mg every 14 days for three doses) as a bridge to CAR-T cell therapy. The patient developed severe immune-checkpoint inhibitor encephalitis with status epilepticus and hypothalamic dysfunction which was treated with intravenous methylprednisolone and intravenous immunoglobulins...He remains clinically stable, with occasional hypothermia from his hypothalamic injury. This case is notable for (1) a rare presentation of EBV-positive DLBCL with CNS involvement in an immunocompetent patient (2) a successful clinical response to..."

Clinical • IO biomarker • B Cell Lymphoma • CNS Disorders • Diffuse Large B Cell Lymphoma • Epilepsy • Epstein-Barr Virus Infections • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma

Crescentic Membranous Nephropathy: An Unusual Complication of Immune Checkpoint Inhibitor Therapy (KIDNEY WEEK 2025) - "He was maintained on nivolumab and cabozantinib - started 2 months prior to presentation...Subsequently, the patient received intravenous methylprednisolone (250 mg daily for 3 days), followed by oral prednisone taper, 5 sessions of plasmapheresis, then rituximab infusion...Existing literature suggests that aggressive immunosuppressive therapy - corticosteroids with cyclophosphamide or rituximab, with or without plasmapheresis - may be beneficial...However, even with prompt treatment, a substantial proportion of patients are at risk for progression to chronic kidney disease or end-stage renal disease. Large-scale studies are needed to enhance our understanding and inform future management strategies."

Checkpoint inhibition • Chronic Kidney Disease • Dyslipidemia • Endocrine Disorders • Fatigue • Genito-urinary Cancer • Glomerulonephritis • Hypertension • Nephrology • Oncology • Prostate Cancer • Renal Cell Carcinoma • Renal Disease • Solid Tumor

Presentation, imaging and 30-day outcomes of immune-checkpoint inhibitor-induced myocarditis: real-world experience from the United Kingdom (ESMO-IO 2025) - "Regimens comprised: 13/33 (39.4%) ipilimumab + nivolumab, 12/33 (36.4%) pembrolizumab, 6/33 (18.2%) atezolizumab, 2/33 (6.1%) nivolumab...Intravenous methylprednisolone was first-line therapy in 32/33 (97.0%), initiated within 24 hours in 56.3% of patients...Triple M syndrome occurred in 5/33 (15.2%) with 30-day mortality of 1/5 (20.0%).Conclusions ICI-myocarditis presented early and was associated with substantial 30-day mortality and complications. Diagnosis remains a challenge, with CMR positive in only 56% of cases.Legal entity responsible for the study Royal Free London NHS Foundation Trust."

Checkpoint inhibition • Clinical • Real-world • Real-world evidence • Genito-urinary Cancer • Melanoma • Mesothelioma • Oncology • Renal Cell Carcinoma • Solid Tumor

Public health implications of delayed diagnosis and treatment of optic neuritis in low-resource settings: a retrospective study of visual recovery outcomes. (PubMed, Front Ophthalmol (Lausanne)) - "Patients were given intravenous methylprednisolone (1 g/day for 3-5 days) and a tapered course of oral prednisolone...In low-resource settings, the short-term visual outcomes of ON are worse with a delay in management. Prompt initiation of corticosteroids and improved referral pathways may aid in maximizing the recovery rate."

Journal • Retrospective data • Ocular Inflammation • Ophthalmology • Optic Neuritis

Comparative effectiveness of corticosteroid injections for trigger finger: A systematic review of randomized controlled trials. (PubMed, J Plast Reconstr Aesthet Surg) - "Methylprednisolone appeared more effective and better tolerated than triamcinolone in trigger finger treatment. Injection technique and adjunctive therapies, such as splinting, had a limited impact on outcomes. Further research is needed to tailor treatment to individual patient characteristics. Systematic review Level I."

HEOR • Journal • Review • Inflammation • Pain

PAGE1: 1-hour Premedication for Allergy Goal in Emergency: PAGE-1 Study (clinicaltrials.gov) - P=N/A | N=426 | Not yet recruiting | Sponsor: Paul Peng, MD PhD MSCR

Head-to-Head • New trial • Allergy • Immunology

A Study of CYP-001 in Combination With Corticosteroids in Adults With High-risk aGvHD (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: Cynata Therapeutics Limited | Trial completion date: Jun 2027 ➔ Dec 2027 | Trial primary completion date: Oct 2025 ➔ Mar 2026

Trial completion date • Trial primary completion date • Acute Graft versus Host Disease • Graft versus Host Disease • Immunology

A practical approach to immune thrombocytopenia in pregnancy. (PubMed, Hematology Am Soc Hematol Educ Program) - "We review options for first-line therapies for ITP in pregnancy, including corticosteroids (prednisone or methylprednisolone) and intravenous immune globulin, which has a favorable safety profile in pregnancy, and second-line therapy options that have been used in pregnancy including thrombopoietin receptor agonists, rituximab, and certain immunosuppressant medications such as azathioprine. We summarize the recommendations for platelet targets for delivery, recognizing that the evidence is limited, including a platelet count of 50  ×  109/L or higher for caesarean delivery and 70  ×  109/L or higher for neuraxial anesthesia. Treatment decisions for ITP in pregnancy should be informed by patients' values and preferences along with a multidisciplinary team that includes hematologists, obstetricians, and anesthesiologists."

Journal • Review • Anesthesia • Hematological Disorders • Immune Thrombocytopenic Purpura • Obstetrics • Thrombocytopenia • Thrombocytopenic Purpura

Metastatic Malignancy Masquerading as Skin Rash. (PubMed, Cureus) - "He received conservative management of the skin symptoms from dermatology, high-dose intravenous methylprednisolone, intravenous immunoglobulins from rheumatology and palliative management of painful rash and limbs...However, this was not possible given the severity of his DM. Prognosis calculation in this situation also proved difficult."

IO biomarker • Journal • Dermatology • Dermatomyositis • Immunology • Lung Adenocarcinoma • Lung Cancer • Myositis • Non Small Cell Lung Cancer • Oncology • Pain • Palliative care • Rheumatology • Solid Tumor

Upadacitinib Combined With Corticosteroids vs Corticosteroid Monotherapy Induction for Inpatients and Outpatients With Acute Severe Ulcerative Colitis (clinicaltrials.gov) - P4 | N=110 | Not yet recruiting | Sponsor: Berinstein, Jeffrey

Monotherapy • New P4 trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Clinical profile and outcome of patients with ANCA-associated vasculitis with special reference to vasculitis damage index: a longitudinal observational study. (PubMed, Rheumatol Int) - "The majority received treatment with intravenous methylprednisolone (46; 79.3%) and intravenous cyclophosphamide (42; 72.4%) during the induction phase, while rituximab (28; 48.3%) was the preferred first-line maintenance agent. Higher Birmingham Vasculitis Activity Score (BVAS) at presentation (OR: 1.25, 95% CI 1.031-1.522) and relapse of scleritis (OR: 35.27, 95% CI 1.152 -1000.000) were found to be independent predictors of high VDI ≥ 5. This is the first study from Eastern India that has looked into the clinical profile of AAV and its damage index."

Journal • Observational data • ANCA Vasculitis • Cardiovascular • Cataract • Diabetes • Hypertension • Metabolic Disorders • Musculoskeletal Diseases • Ocular Inflammation • Ophthalmology • Osteoporosis • Rare Diseases • Rheumatology • Scleritis • Vasculitis